Glaxosmithkline PLC, 10% Owner at Innoviva, Inc. (INVA), sold 32,005,260 shares at $12.25 ($392.1M) on 2021-05-20, disclosed to the SEC on 2021-05-24.
Open-market sale of $392.1M INVA by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| BCYC | SELL | 2020-09-18 | $151K | — | Filing → |
| GNCA | BUY | 2020-07-30 | $2.8M | — | Filing → |
| PAND | BUY | 2020-07-22 | $6.5M | — | Filing → |